Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-20. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0000905148-26-003840
acquired disposedD
codeS
direct or indirectD
form4
is derivativefalse
issuer nameAcrivon Therapeutics, Inc.
labelOpen market sale
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0000905148-26-003840",
"acquired_disposed": "D",
"code": "S",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "Acrivon Therapeutics, Inc.",
"label": "Open market sale",
"person_name": "Peterson Katharine",
"price": 2.01,
"role": "Chief Accounting Officer",
"security": "Common Stock",
"shares": 101,
"shares_owned_after": 18033,
"source_path": "edgar/data/1781174/0000905148-26-003840.txt",
"ticker": "ACRV",
"transaction_date": "2026-08-18",
"value": 203.01
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.